Authors

Latest:

Dr Hecht on Barriers to Enrollment into the BASECAMP-1 Study in Solid Tumors

J. Randolph (Randy) Hecht, MD, discusses barriers to enrollment in the observational BASECAMP-1 study and the phase 1/2 EVEREST-1 study, which will investigate HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in patients with solid tumors.

Michael Schweizer, MD

Latest:

Dr. Schweizer on the Results of the HERO Trial in Prostate Cancer

Michael Schweizer, MD, discusses the results of the HERO trial in prostate cancer.

Shuntaro Ikegawa, MD, PhD

Latest:

Dr Ikegawa on An Analysis of Rapidly Manufactured Durcabtagene Autoleucel in R/R Multiple Myeloma

Shuntaro Ikegawa, MD, PhD, discusses results from a correlative analysis of an ongoing phase 1 trial evaluating the use of a novel T-Charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T-cells in multiple myeloma.

Josep Maria Piulats Rodriguez, MD, PhD

Latest:

Dr Piulats on Validating Predictive Biomarkers for Talazoparib Plus Enzalutamide in mCRPC

Josep Maria Piulats Rodriguez, MD, PhD, discusses next steps for validating predictive biomarkers of efficacy to treatment with talazoparib plus enzalutamide in mCRPC.

Hiba Khan, MD, MPH

Latest:

Dr Khan on the Effects of Financial Toxicity on Survival Outcomes in Patients With Cancer

Hiba Khan, MD, MPH, discusses how adverse financial events may contribute to the risk of early mortality in patients with cancer.

Andrew B. Smitherman, MD, MSc

Latest:

Biomarkers Help Predict the Role of Chemotherapy in Biologic Aging

Stimuli for biologic aging include ionizing radiation, ultraviolet light, diet, exercise, oxidative stresses, and perhaps, worst of all, smoking. All of these can trigger intracellular processes, including DNA methylation, or epigenetic change, telomere shortening and damage, DNA damage, and mitochondrial dysfunction.

Rom S. Leidner, MD

Latest:

Dr Leidner on the DPV-001 Vaccine Plus PD-1 Inhibition in Metastatic HNSCC

Rom S. Leidner, MD, discusses the rationale for studying DPV-001 plus PD-1 inhibition in advanced or metastatic head and neck squamous cell carcinoma.

Samuel Yamshon, MD

Latest:

DIssecting the Current Treatment Landscape for R/R Follicular Lymphoma

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.

Sponsored by AstraZeneca

Latest:

Lung Cancer Disparities in Asian Americans

Biomarker testing may be the key to solving some of the racial and ethnic disparities in lung cancer mortality and survival.

Sailaja Darisipudi

Latest:

Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer

Treatment with the oral selective estrogen receptor degrader elacestrant following treatment with CDK4/6 inhibitors improved progression-free survival outcomes vs standard care options in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Christina L. Roland, MD, PhD

Latest:

Dr. Roland on the Rationale to Examine Neoadjuvant Checkpoint Blockade in Sarcoma

Christina L. Roland, MD, MS, FACS, discusses the rationale of a phase 2 study evaluating neoadjuvant checkpoint blockade in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Britt Erickson, MD

Latest:

Dr. Erickson on the Varying Safety Profiles of Select PARP Inhibitors in Ovarian Cancer

Britt Erickson, MD, discusses the toxicity profiles of available PARP inhibitors used in the treatment of patients with ovarian cancer.

Leslie M. Randall, MD, MAS

Latest:

Dr Randall on PROs With Pembrolizumab Plus Chemoradiotherapy in Cervical Cancer

Leslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.

Shakeela Bahadur, MD

Latest:

Dr Bahadur on the Shift in Frontline CDK4/6 Inhibitor Selection in HR+/ HER2– Breast Cancer Breast Cancer

Shakeela Bahadur, MD, discusses how recent data have informed the selection of approved CDK4/6 inhibitors in the frontline setting for patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Sajeve Samuel Thomas, MD

Latest:

Dr. Thomas on the Safety Profile of Lifileucel Plus Pembrolizumab in Advanced Melanoma

Sajeve Samuel Thomas, MD, discusses the safety profile of lifileucel plus pembrolizumab in advanced melanoma.

Rachna Shroff, MD, MS, FASCO

Latest:

The Future of Liver Function Assessments in HCC

Experts emphasize the importance of using multiple liver function assessments for more comprehensive patient evaluation in hepatocellular carcinoma treatment.

Christopher Su, MD, MPH

Latest:

5 Tips for a First-Year Fellow

Christopher Su, MD, MPH, highlights 5 tips for first-year oncology fellows.

Rachel Zeig-Owens, DRPH

Latest:

The Importance of Lung Cancer Screening in Individuals Exposed to the World Trade Center Disaster

Investigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.

Michael A. Davies, MD, PhD

Latest:

Dr. Davies on the Potential Utility of ERK Inhibitors in Melanoma

Michael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.

Vignesh Packiam, MD

Latest:

Dr. Packiam on Safety of Cabazitaxel/Gemcitabine Plus Pembrolizumab in Urothelial Carcinoma

Vignesh Packiam, MD, discusses the adverse effects associated with cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.